KYTX
Kyverna Therapeutics, Inc.
$9.91
+0.23 (+2.38%)
At close · Jul 8
Market Cap
$602.48M
Shares
60,795,212
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.91
Open$9.48
Day$9.35–10.29
52W$2.52–13.67
Avg vol 30d1.1M
Short int6.1M · 10.0% float · 8.4d
Short vol60%
Last earningsMay 12, 2026
DataFeb 2024–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
+14%
above
RSI (14)
67
neutral
MACD trend
Positive
52-week position
66%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+29%
trailing
6-month return
+14%
trailing
YTD return
+5%
this year
Relative strength
+7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.98% of float · ▲ +5.8% MoM · 8.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 2-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
EPS growth
−9%
Y/Y
Free cash flow
$-153.7M
Balance sheet
$124.1M
net cash
Quant / Vol
risk profile
Volatility
104%
annualized · 1-yr
Max drawdown
−36%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 12, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
67
Neutral
MACD trend
Positive
Bullish
52-week position
66%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.98% of float · ▲ +5.8% MoM · 8.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $10 · 66%
52-wk high $14
vs 200-day avg +22%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KYTX
this stock
Kyverna Therapeutics, Inc.
|
$602.48M | +5.4% | — | — | 10.0% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KYTX | +11.2% | +28.5% | +14.4% | +11.2% | +5.4% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +11.4% | +27.7% | +7.0% | +11.4% | -3.9% |